LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Research

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

Mbuagbaw L, Guglielmetti L, Hewison CCH, Bakare N, Bastard M, Caumes E, Frechet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schunemann HJ, Lienhardt C
Download
Download
Abstract
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%-81.9%), and the treatment success rate was 65.8% (95% CI 59.9%-71.3%). Death rate was 11.7% (95% CI 7.0%-19.1%). Up to 91.1% (95% CI 82.2%-95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%-23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.
Countries
ArmeniaFranceGeorgiaSouth Africa
Subject Area
tuberculosis
DOI
10.3201/eid2505.181823.
Published Date
01-May-2019
PubMed ID
31002070
Languages
English
Journal
Emerging Infectious Diseases
Volume / Issue / Pages
Issue 5
Issue Date
01-May-2019
Dimensions Badge